Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARAMIS: Treatments for Isolated Skin Vasculitis
NCT02939573Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jan 2017
- Primary completion
- Dec 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, randomised trial in cutaneous vasculitis (CSVV), polyarteritis nodosa (PAN) and immunoglobulin A vasculitis comparing Colchicine, Dapsone and Azathioprine (3 arms). Primary endpoint: Response to therapy at 6 months. Started Jan 2017; status: recruiting.
02
Drugs
colchicinedapsoneazathioprine
03
Conditions
cutaneous vasculitis (CSVV)polyarteritis nodosa (PAN)immunoglobulin A vasculitis
Beyond the preview
Go deeper on NCT02939573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939573.